Stem Cell Engraftment
CD122+ cells provide barriers to stem cell engraftment
Published in Blood Weekly, October 27th, 2005
According to recent research from Canada, "The nonobese diabetic/severe combined immune deficiency (NOD/SCID) xenotransplantation model has emerged as a widely used assay for human hematopoietic stem cells; however, barriers still exist that limit engraftment.
"We previously identified a short-term SCID-repopulating cell (SRC) following direct intrafemoral injection into NOD/SCID mice, whereas others characterized similar SRCs using NOD/SCID mice depleted of natural killer (NK) cell activity."
"To determine the model that most efficiently detects short-term SRCs," said...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2005-10-27)
More Articles from Blood Weekly
- Hemophilia
U.S. FDA approves room temperature storage of Helixate FS - Stem Cell Research
Hematopoietic stem cells age-related changes favor myelopoiesis - Stem Cell Transplantation
Donor infusions result in residual/relapsed lymphoid malignancy remission - Stem Cell Transplantation
MSC transplantation and hydroxyapatite ceramics treat severe osteochondral damage - Acute Myeloid Leukemia
EMEA grants orphan drug designation to Troxatyl for acute myeloid leukemia - Adverse Drug Reaction
Drugs raise mitochondrial toxicity risk in HIV/hepatitis C-coinfected patients - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
